| Cat. No. | Product Name | Field of Application | Chemical Structure |
|---|---|---|---|
| DC23540 | CCC07-01 | CCC07-01 (CCC 0701) is a novel alkylating compound that is capable of disrupting expression of PD-1, PD-L1 and CTLA-4 genes with IC50 of 15, 10 and 5 nM in cell-base assays. |
|
| DC7319 | CCDC(TGR5-Receptor-Agonist) Featured | CCDC is a otent, selective TGR5 G-protein coupled receptor agonist (pEC50 = 6.8). |
|
| DC9757 | CCF642 Featured | CCF642 is a novel protein disulfide isomerases (PDI) inhibitor. |
|
| DC20867 | CCG 102487 | CCG 102487 is a CCG-2979 analog that reduces streptokinase (SK) activity with little inhibition of group A streptococcal (GAS) growth. |
|
| DC20871 | CCG 2979 | CCG 2979 is a small molecule inhibitor of gene expression of streptokinase (SK), a critical group A streptococcal (GAS) virulence factor. |
|
| DC7979 | CCG1423 Featured | CCG-1423 is a novel inhibitor of RhoA/C-mediated gene transcription that is capable of inhibiting invasion of PC-3 prostate cancer cells in a Matrigel model of metastasis. |
|
| DC10535 | CCG-203971 Featured | CCG-203971 is an inhibitor of SRE activation in the prostate cancer cell line PC-3 (IC50 = 6.4 μM), with 87% inhibition of SRE activation achieved at 100 μM. |
|
| DC11302 | CCG215022 Featured | CCG215022 is a G protein-coupled receptor kinases (GRKs) inhibitor with IC50s of 0.15±0.07 μM, 0.38±0.06 μM and 3.9±1 μM for GRK2, GRK5 and GRK1, respectively. |
|
| DC10977 | CCG-222740 | CCG-222740 (CCG222740) is a pharmacological inhibitor of MRTF/SRF signalling, shows greater inhibitory effect on MRTF/SRF target genes than MRTF-A inhibitor CCG-203971, with IC50 of 5 uM in fibroblast-mediated collagen contraction assay. |
|
| DC20869 | CCG-232601 | CCG-232601 is a potent (IC50=0.55 uM), orally bioavailable Rho/MKL1/SRF transcriptional pathway that target transcriptional factor MRTF. |
|
| DC22819 | CCG-50014 Featured | CCG-50014 is the most potent against the regulator of G-protein signaling protein type 4 (RGS4) (IC50 =30 nM) and is >20-fold selective for RGS4 over other RGS proteins. CCG-50014 binds covalently to the RGS, forming an adduct on two cysteine residues located in an allosteric regulatory site. CCG50014, reduces nociceptive responses and enhances opioid-mediated analgesic effects in the mouse formalin test. |
|
| DC9612 | CCG-63802 | CCG-63802 is a reversible inhibitor of regulator of G-protein signaling (RGS) protein; with greatest potency at RGS4. IC50 value: Target: RGS CCG-63802 is selective amongst RGS proteins, with greatest potency at RGS4. |
|
| DC9613 | CCG-63808 | CCG-63808 is a reversible inhibitor of regulator of G-protein signaling (RGS) proteins. |
|
| DC22050 | CCI-006 | CCI-006 (CCI 006) is a novel inhibitor of MLL-rearranged and CALM-AF10 translocated leukemias that share common leukemogenic pathways. |
|
| DC22049 | CCI-007 | CCI-007 (CCI 007) is a selective inhibitor of MLL-r, CALM-AF10 and SET-NUP214 leukemia with IC50 of 3.5 uM against MLL-r leukemia cell line PER-485. |
|
| DC26030 | CCMI Featured | CCMI is a positive allosteric modulator of α7 neuronal nicotinic acetylcholine receptors (nAChR). |
|
| DC12639 | CCR1 inhibitor 19e | CCR1 inhibitor 19e is a novel potent, selective CCR1 antagonist with IC50 of 6.8 nM, inhibits CCR1chemotaxis in THP-1 cells with IC50 of 28 nM.. |
|
| DC23528 | CCR10 antagonist 1 | CCR10 antagonist 1 is a potent, selective CCR10 antagonist with IC50 of 690 nM. |
|
| DC12177 | CCR2 antagonist 1 | CCR2 antagonist 1 is a high-affinity and long-residence-time CCR2 antagonist, with a Ki of 2.4 nM. |
|
| DC12302 | CCR2 antagonist 3 Featured | CCR2 antagonist 3 is a chemokine receptor 2 (CCR2) antagonist. |
|
| DC11204 | CCR6 inhibitor 35 | CCR6 inhibitor 35 is a potent and selective CCR6 inhibitor with IC50 of 6.0 nM (hCCR6). |
|
| DC20876 | CCT 068127 | CCT 068127 (CCT68127) is a novel potent inhibitor of CDK2 and CDK9 with IC50 of 10 and 90 nM for CDK2/E and CDK9/T, respectively. |
|
| DC8776 | CCT 137690 | CCT 137690 is a potent inhibitor of Aurora kinases (IC50 values are 0.015, 0.019 and 0.025 μM at Aurora A, Aurora C and Aurora B respectively). |
|
| DC20875 | CCT 365623 hydrochloride | CCT 365623 (CCT365623) hydrochloride is a potent, orally active small molecule inhibitor of lysyl oxidase (LOX) with IC50 of 0.89 uM. |
|
| DC20874 | CCT 365623 | CCT 365623(CCT365623, CCT-365623) is a potent, orally active small molecule inhibitor of lysyl oxidase (LOX) with IC50 of 0.89 uM. |
|
| DC7803 | CCT007093 Featured | CCT007093 is a potent PPM1D (WIP1) inhibitor with IC50 of 8.4 μM. |
|
| DC22464 | CCT-018159 | CCT-01815 is a novel potent inhibitor of Hsp90 ATPase activity with IC50 of 7.1 uM. |
|
| DC12283 | CCT020312 | CCT020312 is capable of delivering potent, and eukaryotic initiation factor 2-alpha kinase 3 (EIF2AK3) selective, proliferation control and also is an activator of RNA-like endoplasmic reticulum kinase (PERK). |
|
| DC20872 | CCT-031374 | CCT-031374 is a selective β-catenin signaling inhibitor with IC50 of 6.1 uM. |
|
| DC23168 | CCT128930 | CCT128930 is a potent, selective, ATP-competitive AKT inhibitor with IC50 of 6 nM (AKT2), 28-fold selectivity over the closely related PKA. |
|
